The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies

Sexually Transmitted Diseases

Volumn 33, Issue 7, 2006, Pages 428-436

  Hu, Delphine ^a,c   Hook III, Edward W ^b   Goldie, Sue J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Harvard Initiative for Global Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; FEMALE; HEALTH CARE COST; HUMAN; INFECTION RISK; NONHUMAN; PELVIC INFLAMMATORY DISEASE; QUALITY ADJUSTED LIFE YEAR; SCREENING; UNITED STATES;

ADOLESCENT; ADULT; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MARKOV CHAINS; MASS SCREENING; MODELS, THEORETICAL; PELVIC INFLAMMATORY DISEASE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; UNITED STATES;

EID: 33745679610     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000200577.46261.b0     Document Type: Article

References (69)

1. Centers for Disease Control and Prevention. Tracking the Hidden Epidemics: Trends in STDs in the United States, 2000. Atlanta: Centers for Disease Control and Prevention, 2001.
2. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2001. Atlanta, GA: US Department of Health and Human Services, 2002.
3. Cates W Jr, Wasserheit JN. Genital chlamydial infections: epidemiology and reproductive sequelae. Am J Obstet Gynecol 1991; 164:1771-1781.
4. rd ed. New York, NY: McGraw-Hill, 1999:451-466.
5. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis 2002; 29:497-502.
6. Britton TF, Delisle S, Fine D. STDs and family planning clinics: a regional program for Chlamydia control that works. Am J Gynecol Health 1992; 6:80-87.
7. Scholes D, Stergachis A, Heidrich FE, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996; 334:1362-1366.
8. Howell MR, Gaydos JC, McKee KT Jr, et al. Control of Chlamydia trachomatis infections in female army recruits: cost-effective screening and treatment in training cohorts to prevent pelvic inflammatory disease. Sex Transm Dis 1999; 26:519-526.
9. Centers for Disease Control and Prevention. Chlamydia Prevalence Monitoring Project Annual Report: Sexually Transmitted Disease Surveillance Report Supplement. Atlanta: Centers for Disease Control and Prevention, 2001.
10. Hillis SD, Nakashima A, Marchbanks PA, et al. Risk factors for recurrent Chlamydia trachomatis infections in women. Am J Obstet Gynecol 1994; 170:801-806.
11. Whittington WL, Kent C, Kissinger P, et al. Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study. Sex Transm Dis 2001; 28:117-123.
12. Richey CM, Macaluso M, Hook EW. Determinants of reinfection with Chlamydia trachomatis. Sex Transm Dis 1999; 26:4-11.
13. Rietmeijer CA, Van Bemmelen R, Judson FN, Douglas JM Jr. Incidence and repeat infection rates of Chlamydia trachomatis among male and female patients in an STD clinic: implications for screening and rescreening. Sex Transm Dis 2002; 29:65-72.
14. Burstein GR, Gaydos CA, Diener-West M, et al. Incident Chlamydia trachomatis infections among inner-city adolescent females. JAMA 1998; 280:521-526.
15. Welte R, Kretzschmar M, Leidl R, et al. Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach. Sex Transm Dis 2000; 27:518-529.
16. Howell MR, Quinn TC, Gaydos CA. Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics: a cost-effectiveness analysis of three strategies. Ann Intern Med 1998; 128:277-284.
17. Hu D, Hook EW 3rd, Goldie SJ. Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis. Ann Intern Med 2004; 141:501-513.
18. Boer R, Plevritis S, Clarke L. Diversity of model approaches for breast cancer screening: a review of model assumptions by the Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups. Stat Methods Med Res 2004; 13:525-538.
19. Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004; 29:2229-2236.
20. Burstein GR, Zenilman JM, Gaydos CA, et al. Predictors of repeat Chlamydia trachomatis infections diagnosed by DNA amplification testing among inner city females. Sex Transm Infect 2001; 77:26-32.
21. Buhaug H, Skjeldestad FE, Backe B, Dalen A. Cost-effectiveness of testing for chlamydial infections in asymptomatic women. Med Care 1989; 27:833-841.
22. Buhaug H, Skjeldestad FE, Halvorsen LE, Dalen A. Should asymptomatic patients be tested for Chlamydia trachomatis in general practice? Br J Gen Pract 1990; 40:142-145.
23. Halvorsen LE, Skjeldestad FE, Mecsei R, Dalen A. [Chlamydia trachomatis in cervix uteri specimens among patients in general practice]. Tidsskr Nor Laegeforen 1988; 108:2706-2708.
24. Stamm WE, Guinan ME, Johnson C, et al. Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N Engl J Med 1984; 310:545-549.
25. Golden MR, Schillinger JA, Markowitz L, St Louis ME. Duration of untreated genital infections with Chlamydia trachomatis: a review of the literature. Sex Transm Dis 2000; 27:329-337.
26. McCormack WM, Alpert S, McComb DE, et al. Fifteen-month follow-up study of women infected with Chlamydia trachomatis. N Engl J Med 1979; 300:123-125.
27. Parks KS, Dixon PB, Richey CM, Hook EW 3rd. Spontaneous clearance of Chlamydia trachomatis infection in untreated patients. Sex Transm Dis 1997; 24:229-235.
28. Joyner JL, Douglas JM Jr, Foster M, Judson FN. Persistence of Chlamydia trachomatis infection detected by polymerase chain reaction in untreated patients. Sex Transm Dis 2002; 29:196-200.
29. Paavonen J, Kiviat N, Brunham RC, et al. Prevalence and manifestations of endometritis among women with cervicitis. Am J Obstet Gynecol 1985; 152:280-286.
30. Weström L, Joesoef R, Reynolds G, et al. Pelvic inflammatory disease and fertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992; 19:185-192.
31. Rein DB, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet Gynecol 2000; 95:397-402.
32. Washington AE, Katz P. Cost of and payment source for pelvic inflammatory disease: trends and projections, 1983 through 2000. JAMA 1991; 266:2565-2569.
33. Washington AE, Cates W Jr, Zaidi AA. Hospitalizations for pelvic inflammatory disease: epidemiology and trends in the United States, 1975 to 1981. JAMA 1984; 251:2529-2533.
34. Washington AE, Arno PS, Brooks MA. The economic cost of pelvic inflammatory disease. JAMA 1986; 255:1735-1738.
35. Weström L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 1980; 138:880-892.
36. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) randomized trial. Am J Obstet Gynecol 2002; 186:929-937.
37. Westrom L. Impact of sexually transmitted diseases on human reproduction: Swedish studies of infertility and ectopic pregnancy. In: Sexually Transmitted Disease States Report, NIAID Study Group. Washington, DC, NIH Publications, 1980:43. No 81-2213.
38. Westrom L, Svensson L. Chronic pain after acute pelvic inflammatory disease. In: Belfort P, et al, eds. Advances in Gynecology and Obstetrics, Proceedings of the XIIth World Congress of Gynecology and Obstetrics, Rio de Janeiro, Vol. 6, General Gynecology. Lancashire, UK: Casterton Hall, 1988:265.
39. Magid D, Douglas JM Jr, Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann Intern Med 1996; 124:389-399.
40. Stephen EH, Chandra A. Use of infertility services in the United States: 1995. Fam Plann Perspect 2000; 32:132-137.
41. Black CM, Marrazzo J, Johnson RE, et al. Head-to-head multicenter comparison of DNA probe and nucleic acid amplification tests for Chlamydia trachomatis infection in women performed with an improved reference standard. J Clin Microbiol 2002; 40:3757-3763.
42. Watson EJ, Templeton A, Russell I, et al. The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review. J Med Microbiol 2002; 51:1021-1031.
43. Katz BP, Danos CS, Quinn TS, et al. Efficiency and cost-effectiveness of field follow-up for patients with Chlamydia trachomatis infection in a sexually transmitted diseases clinic. Sex Transm Dis 1988; 15:11-16.
44. Schwebke JR, Sadler R, Sutton JM, Hook EW 3rd. Positive screening tests for gonorrhea and chlamydial infection fail to lead consistently to treatment of patients attending a sexually transmitted disease clinic. Sex Transm Dis 1997; 24:181-184.
45. Teisala K, Heinonen PK, Aine R, et al. Second laparoscopy after treatment of acute pelvic inflammatory disease. Obstet Gynecol 1987; 69:343-346.
46. Wølner-Hanssen P, Weström E. Second-look laparoscopy after acute salpingitis. Obstet Gynecol 1983; 61:702-704.
47. Brihmer C, Kallings I, Nord CE, Brundin J. Second look laparoscopy: evaluation of two different antibiotic regimens after treatment of acute salpingitis. Eur J Obstet Gynecol Reprod Biol 1989; 30:263-274.
48. Dean D, Ferrero D, McCarthy M. Comparison of performance and cost-effectiveness of direct fluorescent-antibody, ligase chain reaction, and PCR assays for verification of chlamydial enzyme immunoassay results for populations with a low to moderate prevalence of Chlamydia trachomatis infection. J Clin Microbiol 1998; 36:94-99.
49. Gift T, Walsh C, Haddix A, Irwin KL. A cost-effectiveness evaluation of testing and treatment of Chlamydia trachomatis infection among asymptomatic women infected with Neisseria gonorrhoeae. Sex Transm Dis 2002; 29:542-551.
50. Steece R. National Pricing of Chlamydia Reagents. Washington, DC: Association of State and Territorial Public Health Laboratory Directors, 1997.
51. Medical Economics. Drug Topics Red Book. Montvale, NJ: Medical Economics, 2000.
52. Tao G, Gift TL, Walsh CM, et al. Optimal resource allocation for curing Chlamydia trachomatis infection among asymptomatic women at clinics operating on a fixed budget. Sex Transm Dis 2002; 29:703-709.
53. Medicare Part B Reimbursement. Crompond, NY: Health Care Financing Administration, 2000.
54. Yeh JM, Hook EW 3rd, Goldie SJ. A refined estimate of the average lifetime cost of pelvic inflammatory disease. Sex Transm Dis 2003; 30:369-378.
55. Appendix 2: Chlamydia. In: Stratton KR, Durch JS, Lawrence RS, eds. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: National Acad Press, 2000:149-158.
56. U.S. Department of Labor Bureau of Labor Statistics. Highlights of Women's Earnings in 2000: Report 952. Washington, DC: U.S. Department of Labor Bureau of Labor Statistics, 2001. Available at: http://www.bls.gov/cps/ cpswom2000.pdf. Accessed February 26, 2003.
57. SIG Health Care Information Netherlands. Medische Registratie Gepoolde Gegevens over 1993. Utretcht, The Netherlands: SIG, 1994.
58. Groseclose SL, Zaidi AA, DeLisle SJ, Levine WC, St Louis ME. Estimated incidence and prevalence of genital Chlamydia trachomatis infections in the United States, 1996. Sex Transm Dis 1999; 26:339-344.
59. Nsuami M, Cohen DA. Participation in a school-based sexually transmitted disease screening program. Sex Transm Dis 2000; 27:473-479.
60. Mertz KJ, Schwebke JR, Gaydos CA, et al. Screening women in jails for chlamydial and gonococcal infection using urine tests: feasibility, acceptability, prevalence, and treatment rates. Sex Transm Dis 2002; 29:271-276.
61. Stamm WE. Chlamydia trachomatis: the persistent pathogen: Thomas Parran Award Lecture. Sex Transm Dis 2001; 28:684-689.
62. Stamm WE. Chlamydia screening: expanding the scope. Ann Intern Med 2004; 141:570-572.
63. van Valkengoed IG, Morre SA, van den Brule AJ, et al. Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes: implications for cost-effectiveness analyses. Int J Epidemiol 2004; 33:416-425.
64. Morre SA, van den Brule AJ, Rozendaal L, et al. The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. Int J STD AIDS 2002; 13(suppl 2):12-18.
65. Fortenberry JD, Evans DL. Routine screening for genital Chlamydia trachomatis in adolescent females. Sex Transm Dis 1989; 16:168-172.
66. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford Univ Press, 1996.
67. Graham JD, Corso PS, Morris JM, et al. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health 1998; 19:125-152.
68. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 1995. Atlanta, GA: US Department of Health and Human Services, 1996.
69. Weite R, Postma M, Leidl R, Kretzschmar M. Costs and effects of chlamydial screening: dynamic versus static modeling. Sex Transm Dis 2005; 32:474-483.